A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily
Public ClinicalTrials.gov record NCT01814137. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST®: INTENSIFY BID)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is conducted globally. The aim of the trial is to compare efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) + insulin aspart (IAsp) once daily (OD) versus basal bolus with insulin degludec (IDeg) OD + IAsp three times a day (TID) in controlling glycaemia by evaluating glycosylated haemoglobin (HbA1c). The trial is an extension to trial NN5401-3941 (NCT01680341).
Study identification
- NCT ID
- NCT01814137
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2013 (Type not available)
- Primary completion
- Mar 2014 (Actual)
- Completion
- Mar 2014 (Actual)
- Last update posted
- Mar 21, 2017
2013 – 2014
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Goodyear | Arizona | 85395 | — |
| Novo Nordisk Investigational Site | Phoenix | Arizona | 85020 | — |
| Novo Nordisk Investigational Site | Anaheim | California | 92801 | — |
| Novo Nordisk Investigational Site | Greenbrae | California | 94904 | — |
| Novo Nordisk Investigational Site | San Diego | California | 92111 | — |
| Novo Nordisk Investigational Site | Spring Valley | California | 91978 | — |
| Novo Nordisk Investigational Site | Bradenton | Florida | 34201 | — |
| Novo Nordisk Investigational Site | Kissimmee | Florida | 34741 | — |
| Novo Nordisk Investigational Site | Plantation | Florida | 33324 | — |
| Novo Nordisk Investigational Site | Avon | Illinois | 46123 | — |
| Novo Nordisk Investigational Site | Crystal Lake | Illinois | 60012 | — |
| Novo Nordisk Investigational Site | Indianapolis | Indiana | 46254 | — |
| Novo Nordisk Investigational Site | Slidell | Louisiana | 70461-4231 | — |
| Novo Nordisk Investigational Site | Waltham | Massachusetts | 02453 | — |
| Novo Nordisk Investigational Site | Buckley | Michigan | 49620 | — |
| Novo Nordisk Investigational Site | Nashua | New Hampshire | 03063 | — |
| Novo Nordisk Investigational Site | Lawrenceville | New Jersey | 08648 | — |
| Novo Nordisk Investigational Site | Toms River | New Jersey | 08755-8050 | — |
| Novo Nordisk Investigational Site | Albany | New York | 12206 | — |
| Novo Nordisk Investigational Site | Myrtle Beach | South Carolina | 29572 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75230 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75251 | — |
| Novo Nordisk Investigational Site | Fort Worth | Texas | 76132 | — |
| Novo Nordisk Investigational Site | Olympia | Washington | 98502 | — |
| Novo Nordisk Investigational Site | Tacoma | Washington | 98405 | — |
| Novo Nordisk Investigational Site | Kenosha | Wisconsin | 53142 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01814137, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2017 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01814137 live on ClinicalTrials.gov.